08 Aug Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer
Posted at 11:37h in Blogs 0 Comments
In patients with previously untreated locally advanced or metastatic TNBC, the addition of pembrolizumab to chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine–carboplatin) resulted in significantly longer overall survival than chemotherapy alone in the CPS-10 subgroup (PD-L1 expression scores of ≥ 10). No new safety signals emerged. (Ref: Cortes J et al. N Engl J Med. July 21, 2022)
Sorry, the comment form is closed at this time.